[Pubmed] Safety and efficacy of therapeutic plasma exchange in pediatric neuro-immunological diseases

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6515
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Mac OS X iPhone

[Pubmed] Safety and efficacy of therapeutic plasma exchange in pediatric neuro-immunological diseases

Message par RSS-Bot »


Adv Med Sci. 2025 Jan 15:S1896-1126(25)00003-3. doi: 10.1016/j.advms.2025.01.003. Online ahead of print.

ABSTRACT

PURPOSE: Therapeutic plasma exchange (TPE) is the treatment of choice in various neuro-immunological disorders in pediatric populations. This study assesses the safety and efficacy of TPE in this demographic.

MATERIALS AND METHODS: A single-center, retrospective cohort study involving pediatric patients who experienced neuro-immunological events and underwent TPE procedures at a tertiary referral center was conducted.

RESULTS: The study included 81 patients (Guillain-Barre: 65, polyneuropathies: 5, myasthenia gravis: 8, multiple sclerosis: 3), undergoing collectively 360 TPE procedures. Fresh frozen plasma (FFP) was used in 76.1% of the TPE procedures. Adverse events (AEs) occurred in 50% of TPEs using FFP compared to 39.5% without. For procedures with at least two AEs, the rates were 24.5% with FFP vs 8.1% without. Incidence of allergic AEs was significantly higher in the FFP group (94.2% of TPE with at least one AE) compared to those without FFP (47.2%). Serious AE accounted for 1.2% of TPE procedures and 2.5% of patients. Effectiveness evaluations using a scale developed for this study and the Hughes Functional Grading Scale showed no significant clinical pre-treatment differences. After completing the treatment, children in the polyneuropathies group had the most severe clinical condition, and the largest relative improvement in clinical status was in the myasthenia gravis group.

CONCLUSIONS: TPE conducted by filtration is an effective and safe therapy for pediatric neuro-immunological diseases, with benefits outweighing the risks of complications. The use of FFP in therapy increases the probability of AE by 27%, and significantly raises the risk of allergic and multiple AEs.

PMID:39824387 | DOI:10.1016/j.advms.2025.01.003


Source: https://pubmed.ncbi.nlm.nih.gov/3982438 ... t9+e462414
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »